Hi,
moomoo ID:NaN
Log Out
English
Back
Download
Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > APGNW APEXIGEN INC C/WTS 29/07/27 (TO PUR COM) > Detailed Quotes

APGNW APEXIGEN INC C/WTS 29/07/27 (TO PUR COM)

Watchlist
0.108
-0.005-4.42%
Close  02/03 16:00 ET
High
0.113
Open
0.113
Turnover
1.99K
Low
0.100
Pre Close
0.113
Volume
17.80K
Market Cap
0
P/E(TTM)
0.00
52wk High
0.876
Shares
0
P/E(Static)
0.00
52wk Low
0.022
Float Cap
0
Bid/Ask %
66.67%
Historical High
0.876
Shs Float
0
Volume Ratio
1.31
Historical Low
0.022
Dividend TTM
--
Div Yield TTM
--
P/B
0.00
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.00%
Amplitude
11.02%
Avg Price
0.111
Lot Size
1
Float Cap
0
Bid/Ask %
66.67%
Historical High
0.876
Shs Float
0
Volume Ratio
1.31
Historical Low
0.022
Dividend TTM
--
P/B
0.00
Dividend LFY
--
Turnover Ratio
0.00%
Amplitude
11.02%
Avg Price
0.111
Lot Size
1
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast

News

Comment

News

Announcement

No Data

Company Overview More
Apexigen(formerly Brookline Capital Acquisition Corp.) is a clinical-stage biopharmaceutical company focused on developing innovative antibody therapies for the treatment of cancer with an immuno oncology focus. Apexigen has built a diversified pipeline of wholly owned and collaborative assets using its proprietary APXiMAB ? antibody discovery platform. The company's primary asset, Sotigalimab, is potentially the best-in-class and best-in-class CD40 agonist with unique epitope specificity and Fc receptor binding to achieve optimal therapeutic outcomes.
CEO： Dr. Xiaodong Yang, M.D.
Market： NASDAQ
Listing Date： 01/29/2021
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Get Started
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist